Young David 4
4 · Processa Pharmaceuticals, Inc. · Filed Apr 11, 2025
Insider Transaction Report
Form 4
Young David
DirectorPres. Research & Development
Transactions
- Tax Payment
Common Stock
2025-04-01$0.41/sh−5,345$2,202→ 217,332 total - Exercise/Conversion
Common Stock
2025-04-01+17,272→ 222,677 total
Holdings
- 30,985(indirect: By Trust)
Common Stock
- 10,786(indirect: By Family Entities)
Common Stock
- 18,544(indirect: By LLC)
Common Stock
Footnotes (1)
- [F1]Distribution of vested restricted shares.